Overview

Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if the addition of mangosteen juice to standard medical care will reduce the risk of atrial fibrillation (AF) recurrence following direct current (DC) cardioversion. The study will also look at the effects the mangosteen juice may have on biomarkers of inflammation and endothelial cell dysfunction (the tissue lining the arteries does not function properly).
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic